The observation that soluble mesothelin, the reference biomarker of mesothelioma,19 was not found to be differentially expressed in mesotheliomas when compared to lung adenocarcinomas may be explained by the use of a different platform assay and the fact that a quarter of advanced lung adenocarcinomas express high levels of mesothelin.20 This evidence concerns the gene MSLN and lung adenocarcinoma.